Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837602 · ClinicalTrials.gov registry record · Phase 1
cMet CAR RNA T Cells Targeting Breast Cancer
A Phase 1 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01837602 is a Phase 1 study of Metastatic Breast Cancer and Triple Negative Breast Cancer that has completed, run by University of Pennsylvania. The registered enrollment target is 6 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01837602, a Phase 1 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
An open-label, clinical trial of autologous cMet redirected T cells administered intratumorally (IT) in patients with breast cancer. Fifteen evaluable patients will be enrolled in stepwise fashion. Step 1 will enroll patients with metastatic breast cancer refractory to at least 1 standard therapy, step 2 will include newly diagnosed patients with operable triple negative breast cancer.
Conditions Studied
Interventions
- BIOLOGICAL cMet RNA CAR T cells
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-04 |
| Est. Completion | 2018-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837602
The ClinicalTrials.gov registry entry for NCT01837602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which cMet RNA CAR T cells is the first listed.
NCT01837602 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01837602 about?
NCT01837602 is a clinical study titled "cMet CAR RNA T Cells Targeting Breast Cancer". An open-label, clinical trial of autologous cMet redirected T cells administered intratumorally (IT) in patients with breast cancer. Fifteen evaluable patients will be enrolled in stepwise fashion. Step 1 will enroll patients with metastatic breast cancer refractory to at least 1 standard therapy, s...
What is the current status of trial NCT01837602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-04. Estimated completion is 2018-08-13.
What conditions does trial NCT01837602 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT01837602?
The interventions under investigation include: cMet RNA CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01837602?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01837602 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Breast Cancer
All registered trials for this condition
Triple Negative Breast Cancer
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.